Flarin Revenue and Competitors

London, London

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Flarin's estimated annual revenue is currently $502.5k per year.(i)
  • Flarin's estimated revenue per employee is $100,500

Employee Data

  • Flarin has 5 Employees.(i)
  • Flarin grew their employee count by 150% last year.

Flarin's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.5M25-32%N/AN/A
#2
$0.5M5150%N/AN/A
Add Company

What Is Flarin?

Flarin is the first and only over-the-counter (OTC) lipid formulated ibuprofen 200mg which helps relieve flaring joint pain and inflammation. It is indicated for the relief from rheumatic or muscular pain, back pain, and also for the relief of pain of non-serious arthritic conditions, caused by swelling, stiffness and inflammation. It has been clinically proven to be as effective as prescription strength ibuprofen (2400 mg) at reducing joint pain.A recent clinical study conducted at 27 primary care centres in 462 patients, the first of its kind to focus on flaring joints provided good clinical evidence to show that combining ibuprofen in a lipid formulation can deliver effective flare-up control. Flarin comes in packs of 30 and 12 soft capsules and derives from infirst Ltd portfolio of patented technologies. Essential information: Flarin 200mg soft capsules. Contains ibuprofen. Relief from rheumatic or muscular pain, also for the relief of pain of non-serious arthritic conditions (caused by swelling, stiffness and inflammation of joints), joint pain, back pain. Always read the leaflet. https://flarin.co.uk/wp-content/uploads/2021/10/PFLA_PIL_014_proof_no-panel.pdfhttps://flarin.co.uk/wp-content/uploads/2021/10/GFLA_PIL_005-Proof_No-panel.pdf

keywords:N/A

N/A

Total Funding

5

Number of Employees

$502.5k

Revenue (est)

150%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M50%$7M
#2
$0.4M5-37%N/A
#3
$0.6M5-37%N/A
#4
$0.4M5-58%N/A
#5
$0.3M5-17%N/A